Luncheon Symposium 7【Bayer】
15 Aug 2025
12:00
13:00
TICC - 2F 201BC
Integrating Radioligand Therapy into mCRPC Clinical Practice: From Taiwan Experience
Introduce the treatment options and trends for mCRPC (metastatic castration-resistant prostate cancer) medications and share the Xofigo real-world data from the Tri-Service General Hospital in Taiwan.
| Time | Session |
|---|
|
12:00
13:00
|
Jacob See-Tong PangTaiwan
Moderator
Ming-Hsin YangTaiwan
Speaker
|